Periodontal Intrabony DefectsNCT07160101
Comparison of Effects of Eggshell Derived Nano Hydroxyapatite and Hydroxyapatite in Management of Periodontal Intrabony Defects
A study testing Eggshell derived nano hydroxyapatite and Hydroxyapatite in people with Periodontal Intrabony Defects and Bone Regeneration, run by Dr R Viswa Chandra at 1 site in India.
Trial summary
The aim of the study is to evaluate osseous regenerative efficacy of eggshell derived nanohydroxyapatite in comparison with hydroxyapatite The test group includes patients with intrabony defects where flap surgery will be performed \& Eggshell derived nano hydroxyapatite (ESnHA) is placed. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Periodontal Intrabony Defects, Bone Regeneration
- What is being tested?
- Eggshell derived nano hydroxyapatite and Hydroxyapatite
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteIndia
- Study dates
- 22 Mar 2023to 27 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Presence of Two-walled or three-walled intrabony defects \& Probing pocket depths (PPD) of >5mm after initial therapy Systemically healthy male and female patients of age >18 years
Who cannot join
- Medically compromised patients Pregnant women, Heavy smokers, and Patients who underwent radiotherapy or chemotherapy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: "Comparative Efficacy Of Eggshell Derived Nano Hydroxyapatite Over Hydroxyapatite In The Treatment Of Periodontal Intrabony Defects: A Clinico-Radiographic Study"
The aim of the study is to evaluate osseous regenerative efficacy of eggshell derived nanohydroxyapatite in comparison with hydroxyapatite The test group includes patients with intrabony defects where flap surgery will be performed \& Eggshell derived nano hydroxyapatite (ESnHA) is placed.
Read the detailed description
Experimental : Main treatment group Eggshell derived nano hydroxyapatite is placed into defect site Comparator : In patients allocated to control group, only Hydroxyapatite is placed.
- Conditions
- Periodontal Intrabony Defects, Bone Regeneration
- Being tested
- Eggshell derived nano hydroxyapatite, Hydroxyapatite
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Eggshell derived nano hydroxyapatiteOther
Eggshell derived nano hydroxyapatite has high solubility and allows faster integration \& replaces with osseous tissue
HydroxyapatiteOther
Hydroxyapatite has similar chemical composition with crystalline structure of native bone
| Study group | Role | What they receive |
|---|---|---|
| Test group Eggshell derived nano hydroxyapatite | Experimental | In Test group after flap reflection \& degranulation, bone graft i.e Eggshell derived nano hydroxyapatite is placed into defect. Receives: Other: Eggshell derived nano hydroxyapatite |
| Control group | Active comparator | In Control group, after flap reflection \& debridment bone graft i.e Hydroxyapatite is placed into defect. Receives: Other: Hydroxyapatite |
What is being measured
The primary outcome is the main question the study is designed to answer.
RVG
Radiovisiography will be used to assess bone regeneration achieved post operatively
Measured: 3months & 6months
Probing Depth
Measured: 3 months & 6months
Clinical Attachment Level
Measured: 3 months & 6 months
Secondary outcomes (2)
Full mouth Plaque index
Full mouth plaque index was measured using Turesky modification of the Quigley-Hein Index at baseline, 3 months and 6 months
Measured: 3 months & 6 months
Full mouth Gingival index
Full mouth gingival index was measured using Loe \& Silness Index at baseline, 3 months and 6 months
Measured: 3 months & 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start22 Mar 2023
- Primary completion13 Aug 2024
- Study completion27 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal Intrabony DefectsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 28 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr R Viswa Chandra
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr R Viswa Chandra, SVS Institute of Dental Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07160101
- Sponsor's protocol ID
- SVSIDS/PERIO/1/2022
- Status last verified
- Aug 2025
- First submitted
- 30 Aug 2025
- Last updated
- 15 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Comparative Efficacy Of Eggshell Derived Nano Hydroxyapatite Over Hydroxyapatite In The Treatment Of Periodontal Intrabony Defects: A Clinico-Radiographic Study"
- ClinicalTrials.gov ID
- NCT07160101
- Acronym / sponsor ID
- SVSIDS/PERIO/1/2022
- Conditions
- Periodontal Intrabony Defects, Bone Regeneration
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 28 participants (actual)
- Lead sponsor
- Dr R Viswa ChandraUniversity, hospital or other
- Study start
- 22 Mar 2023 (actual)
- Primary completion
- 13 Aug 2024 (actual)
- Study completion
- 27 Mar 2025 (actual)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to evaluate osseous regenerative efficacy of eggshell derived nanohydroxyapatite in comparison with hydroxyapatite The test group includes patients with intrabony defects where flap surgery will be performed \& Eggshell derived nano hydroxyapatite (ESnHA) is placed.
Detailed description
Experimental : Main treatment group Eggshell derived nano hydroxyapatite is placed into defect site Comparator : In patients allocated to control group, only Hydroxyapatite is placed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test group Eggshell derived nano hydroxyapatite | Experimental | Other: Eggshell derived nano hydroxyapatiteIn Test group after flap reflection \& degranulation, bone graft i.e Eggshell derived nano hydroxyapatite is placed into defect. |
| Control group | Active comparator | Other: HydroxyapatiteIn Control group, after flap reflection \& debridment bone graft i.e Hydroxyapatite is placed into defect. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Presence of Two-walled or three-walled intrabony defects \& Probing pocket depths (PPD) of >5mm after initial therapy Systemically healthy male and female patients of age >18 years
Key exclusion criteria (1 listed)
- Medically compromised patients Pregnant women, Heavy smokers, and Patients who underwent radiotherapy or chemotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Eggshell derived nano hydroxyapatiteEggshell derived nano hydroxyapatite has high solubility and allows faster integration \& replaces with osseous tissue | Other | Test group Eggshell derived nano hydroxyapatite |
| HydroxyapatiteHydroxyapatite has similar chemical composition with crystalline structure of native bone | Other | Control group |
Primary outcome
RVG
Time frame: 3months & 6months
Radiovisiography will be used to assess bone regeneration achieved post operatively
Probing Depth
Time frame: 3 months & 6months
Clinical Attachment Level
Time frame: 3 months & 6 months
2 secondary outcomes
Full mouth Plaque index
Time frame: 3 months & 6 months
Full mouth Gingival index
Time frame: 3 months & 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Periodontal Intrabony Defects
Recruiting
A Closed Surgical Technique vs Modified Papilla Preservation Technique
Intrabony Periodontal Defect, Treatment
Recruiting
Treating Intrabony Defect With MINST VS MINST Extended PRF
Periodontal Intrabony Defects
Not yet recruiting
Minimally Invasive Non-Surgical Therapy Versus Single Flap Approach in Management of Periodontal Intrabony Defects
Intrabony Periodontal Defects
Recruiting
Treatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts
Periodontitis, Intrabony Periodontal Defect
Not yet recruiting
Alb-PRF as an Adjunct to Regenerative Periodontal Surgery
Periodontitis, Periodontitis Stage III
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Eggshell derived nano hydroxyapatite and Hydroxyapatite in people with Periodontal Intrabony Defects and Bone Regeneration, run by Dr R Viswa Chandra at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
RVG (time frame: 3months & 6months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.